Epstein-Barr virus latent membrane protein 2-derived peptides presented by class I human leukocyte antigen (HLA) alleles (EBV LMP2/HLA-I complex)

Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) is a viral protein expressed during the latent phase of EBV infection, particularly in Latency II and III programs. It plays a critical role in maintaining viral latency and promoting oncogenesis by mimicking B-cell receptor signaling, which prevents apoptosis in infected cells. Peptides derived from the LMP2 protein are processed intracellularly and presented on the cell surface by Class I Human Leukocyte Antigen (HLA) molecules. These peptide-HLA complexes serve as highly specific targets for CD8+ cytotoxic T-lymphocytes (CTLs), which recognize the foreign viral epitopes and initiate cell-mediated lysis. Because LMP2 is consistently expressed in EBV-associated malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma, it is a primary target for immunotherapies. Current therapeutic strategies include adoptive T-cell transfers, T-cell receptor (TCR) engineered T-cells, and therapeutic vaccines designed to enhance the immune system's ability to eliminate EBV-positive tumor cells while sparing healthy tissue.

Other names

LMP2-HLA complexEBV LMP2 peptide-MHCLatent membrane protein 2 epitopesLMP2A/B-derived HLA-I peptidesEBV-specific T-cell target

Binding of therapeutic T-cell receptors (TCRs) or endogenous cytotoxic T-lymphocytes to the peptide-HLA complex, triggering the release of perforins and granzymes to induce apoptosis in EBV-infected or malignant cells.